Aicuris tables nasty news for bugs
Germany’s Bayer spin-off AiCuris GmbH & Co. KG has tabled positive results from a combined Phase II safety/efficacy study with its non-nucleosidic herpes simplex virus (HSV) inhibitor AIC316 in 156 patients with Type 2-genital herpes. At the highest of 4 doses (5, 25, and 75 mg once daily, or 400 mg once weekly) administered versus placebo over 4 weeks, AIC316 led to a significant reduction of the amount of HSV found and correlated with a significant clinical benefit. According to the company, the proportion of days with reported genital lesions was reduced from 13.7% to 1.1%, and number of recurrences dropped substantially as well. AiCuris’ CEO Helga Rübsamen-Schaeff said that the drug also showed a good safety profile.